![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 9, 6767-6770, March 1, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
From the Department of Pharmacology and Experimental Therapeutics,
Louisiana State University Health Science Center, New Orleans,
Louisiana 70118, the
Department of Library and
Informatics, Medical University of South Carolina, Charleston, South
Carolina 29425, and the § Department of Biochemistry and
Molecular Pharmacology, West Virginia University School of Medicine,
Morgantown, West Virginia 26506
Received for publication, December 3, 2001
| |
ABSTRACT |
|---|
|
|
|---|
The G-protein regulatory (GPR) motif, a conserved
25-30 amino acid domain found in multiple mammalian proteins,
stabilizes the GDP-bound conformation of
G The activation/deactivation cycle of heterotrimeric G-proteins,
key players in cell signaling events, involves guanine nucleotide exchange, GTP hydrolysis, and a number of dynamic, conformationally sensitive protein interactions. In addition to the extensively studied
activation of G-proteins by the superfamily of G-protein-coupled receptors, the G-protein activation/deactivation cycle is regulated by
nonreceptor proteins that influence subunit interactions, GTPase activity, and guanine nucleotide binding properties of G Surprisingly, interaction of the GPR motif with G The existence of such a fairly discrete and highly conserved binding
motif that inhibits GDP dissociation is of particular interest. As a
first step toward developing a small organic molecule that would mimic
the action of a GPR peptide, we defined the key structural features of
the GPR motif required for biological activity. These data provide a
platform for the development of novel, G-protein-selective therapeutics
that target this critically important signaling protein within the
cell. Such agents might inhibit G Materials--
Peptides were synthesized and purified by
Bio-Synthesis, Inc. (Lewisville, TX) and peptide identity verified by
matrix-assisted laser desorption ionization mass spectrometry. Peptides
were synthesized with an acetylated amino terminus and an amidated
carboxyl terminus. All other materials were obtained as described
elsewhere (3-5).
GTP Stabilization of the GDP-bound conformation of G
i, inhibits guanosine
5'-O-(3-thiotriphosphate) (GTP
S) binding to
G
i and competes for G
binding to G
. To define
the core GPR motif and key amino acid residues within a GPR peptide
(TMGEEDFFDLLAKSQSKRMDDQRVDLAG), we determined the effect of truncation,
insertion, and alanine substitutions on peptide-mediated inhibition of
GTP
S binding to purified G
i1. The bioactive core GPR
peptide consists of 17 amino acids
(7F-R23). Within this core motif, two
hydrophobic sectors (7FF8 and
10LL11) and Q22 are required for
bioactivity, whereas M19A and R23A increased IC50
values by 70-fold. Disruption of spatial relationships between the
required sectors in the amino and carboxyl regions of the peptide also
resulted in a loss of biological activity. Mutation of three charged
sectors (4EED6, R18,
20DD21) within the 28-amino acid GPR decreased
peptide affinity by ~10-fold. Alanine substitutions of selected
residues within the core GPR peptide differently influenced peptide
inhibition of GTP
S binding to G
i versus
G
o. These data provide a platform for the development of
novel, G-protein-selective therapeutics that inhibit
G
i-mediated signaling, selectively activate
G
-sensitive effectors, and/or disrupt specific regulatory input
to G-proteins mediated by GPR-containing proteins.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
. One signature motif for such regulatory proteins is the regulator of
G-protein signaling (RGS)1
domain, a ~120-amino acid motif found in all members of the RGS family (1). Another signature motif (~25-30 amino acids) is defined
by the G-protein regulatory (GPR) domain in activator of G-protein
signaling (AGS) 3 (2-6), which was discovered in a functional screen
for receptor-independent activators of G-protein signaling. The GPR
motif was also recognized in RGS12 and RGS14 by general sequence
analysis/alignment and termed the GoLOCO motif (7, 8).
i
stabilizes the GDP bound conformation of G
i, competes
with G
for G
binding, and inhibits guanine nucleotide exchange
(3-6, 9-12). Thus, the GPR motif acts as a guanine nucleotide
dissociation inhibitor of G
i. The GPR motif is
evolutionarily conserved within individual orthologs and among proteins
with apparently diverse functions (see S.M.A.R.T. data base at
dylan.embl-heidelberg.de/). Four spatially conserved GPR
motifs are found in AGS3 (3) and LGN (13), which were isolated
as G
i-regulatory/binding proteins. Recombinant AGS3
constructs with more than one GPR motif actually bind more than one
G
i at the same time (5), suggesting a scaffolding role
for such proteins. The AGS3/LGN-related protein PINS, which plays key
roles in cell polarity (14-17), possesses a similar domain structure.
The interaction of the PINS protein GPR domains with G
is involved
in the function of PINS in cell polarity and asymmetric cell division
(17). AGS3 is also involved in synaptic adaptation in rat models of
addiction (22). Single GPR motifs are found in Rap1GAP, Pcp2, RGS12,
and RGS14, which are all implicated as G-protein regulators. Protein
interaction studies and/or functional screens in yeast indicate that
the AGS3 GPR motif interacts with G
i1-3, but not
G
s, G
q, G
z,
G
12, or G
16 (3, 5, 11). Specific GPR
motifs are capable of interacting with G
o, albeit with
apparently lower affinity than observed for G
i (10). Rap1GAP was actually isolated in yeast two-hybrid screens using G
o (18) and G
z (19), whereas Pcp2 was
isolated in similar screens using G
o (20). Thus the GPR
motif appears to serve as a discrete motif to anchor a variety of
proteins that influence the guanine nucleotide binding/hydrolysis
properties of G-proteins.
-mediated signaling by
G-protein-coupled receptors, selectively activate G
-sensitive effectors, and/or disrupt specific regulatory input to G-proteins mediated by GPR-containing proteins.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
S Binding and Protein Interaction Assays--
GTP
S
binding assays and protein interaction assays were conducted as
described previously (4, 5). The GPR domain of AGS3
(463P-S650) was generated as a gutathione
S-transferase fusion protein in pGEX4T1. GST-AGS3 was
expressed in and purified from BL21 bacteria using
glutathione-Sepharose 4B. G
i1 and G
o were
purified in the GDP bound state from Sf9 insect cells infected
with recombinant virus as described previously (21). Concentration
response curves with GPR peptides were analyzed by PRISM (Graphpad
Software, Inc, San Diego, CA) to calculate IC50 values.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
i
by a 28-amino acid peptide encompassing the GPR motif presents an
unexpected aspect of regulation within the G-protein
activation/deactivation cycle. This activity of the peptide essentially
prevents nucleotide exchange on G
and binding of GTP to G-protein.
The GPR-G
iGDP complex is quite stable and is observed in
the absence and presence of added magnesium, which is generally
required for high affinity binding of GTP
S (Fig.
1). As part of a broad approach to define the structural properties of this regulation and develop a small molecule ligand that would target this novel regulatory site on G
subunits, we defined the core GPR motif and the key amino acid residues
within this core motif. A panel of peptides derived from the GPR motif
were characterized in GTP
S binding assays and protein interaction
assays using purified mammalian G-protein
subunits.

View larger version (19K):
[in a new window]
Fig. 1.
Effect of magnesium on inhibition of
GTP
S binding to
G
i. GTP
35S
(500 nM) binding (using 0 and 25 mM
MgCl2) to G
i (100 nM) was
measured in absence and presence of increasing amounts of GPR peptide
as described under "Experimental Procedures." Data are expressed as
the percent of specific binding (~2 pmol) observed in the absence of
added peptide and are expressed as the mean ± S.E. of two
experiments with duplicate determinations.
Several conserved features constitute the GPR motif. The invariant
Q15 essentially divides the peptide into two general
regions of conserved residues (Fig.
2A). Both helical wheel and
hydrophobic moment analysis indicate that the area upstream of
Q15 likely exists as an alpha helix. We first asked if
either of the two general regions of conserved residues
(i.e. upstream and downstream of Q15) were
active by themselves. Neither GPR1-15 nor GPR15-28 inhibited GTP
S
binding to G
i. The region upstream of Q15 is
distinguished by the negatively charged 4EED6
followed by two hydrophobic sectors (7FF8,
10LL11) (Fig. 2). The region downstream of the
Q15 peptide is characterized by the conserved sequence
18RMDDQR23. Deletion of the first eight
residues at the amino terminus, which removed
7FF8 or mutation of R23 to
phenylalanine (3-5), resulted in an inactive peptide indicating that
the minimal sequence for bioactivity is 7F-R23
(Fig. 2A). The 20DDQR23 sequence is
one of the most highly conserved regions of the peptide among different
species and proteins. To test the importance of the spatial
relationship between this region and the remainder of the conserved
residues found elsewhere in the peptide, we inserted two and four
alanines just upstream of the 20DDQR23 region.
Insertion of the alanines completely abolished bioactivity in GTP
S
binding assays (Fig. 2A). Thus, these data indicated that
there is a core GPR motif (residues 7-23) in which a defined spatial
relationship among the conserved residues is required for
bioactivity.
|
We then addressed the relative importance of conserved amino acids
within the core GPR motif by alanine substitutions and subsequent
peptide evaluation in GTP
S binding assays (Fig. 2B). Peptides with alanine substitutions at 7FF8,
10LL11, and Q22 were inactive and
thus identify the key residues of the peptide. Both
7FF8 and 10LL11 likely
constitute the core of the predicted alpha helix in this region,
indicating the importance of this structural feature for bioactivity
(Fig. 1). The importance of this region is further emphasized by loss
of biological activity observed with an F8R mutation in the
context of a GST-AGS3 fusion protein (3, 5, 17). The IC50
values for D9A, K13A, Q15A, and S16A peptides were similar to the
consensus GPR peptide (Fig. 2B). Alanine substitutions at
the other key residues within the GPR motif indicated that the residues
could be grouped as those causing 7-10-fold
(4EED6, R18, and
20DD21) or 50-70-fold (M19 and
R23) shifts in IC50 values (Fig.
2B). The loss of affinity observed with the alanine
substitutions at 4EED6 are consistent with the
retention of bioactivity by the truncation mutant GPR3-24, whereas the
loss of activity with the 7FF8 alanine
substitutions was also observed by elimination of these residues in the
GPR10-24 truncated peptide. The larger reduction in affinity observed
with the M19 and R23 alanine substitutions
indicate the importance of these residues within the core GPR peptide.
Indeed, reversal of charge or hydrophobicity at these residues (M19D
and R23F) essentially rendered these peptides inactive
(3-5).2
The inhibition of GTP
S binding and apparent stabilization of the
GDP-bound conformation of G
i by the GPR peptide likely involves two events, the initial binding of the peptide to G-protein, followed by a conformational change in G
i itself. To
determine whether the two events can be functionally dissociated, we
performed two series of experiments. We first asked if mutant peptides
that exhibited lower affinity in GTP
S binding assays were also
deficient in inhibiting binding of a GPR-containing GST-AGS3 fusion
protein to G
i. In the second series of experiments, we
determined whether truncated GPR peptides could act in a complementary
fashion and whether they could antagonize the action of the GPR
consensus peptide. Data generated from this series of experiments
indicated that the loss of function in binding studies was also
reflected in the protein interaction assays (Fig.
3, A and B). The
partial inhibition of GST-AGS3 binding to G-protein in the presence of GPR6-24 indicates that this peptide is not as potent as GPR3-24 or
wild type peptide, likely due to the loss of the
4EED6 acidic cluster (Fig. 2, A and
B, and Fig. 3B). These data indicated that
G-protein interaction and inhibition of GTP
S binding could not be
dissociated from each other. This point is further emphasized by data
generated in another series of experiments (Fig. 3C). A
combination of the inactive GPR truncation peptides (GPR 1-15 and GPR
15-28) did not inhibit binding of GST-AGS3 to G
i.
Neither of the peptides antagonized the action of the consensus GPR
peptide nor were they able to rescue the activity of nonfunctional,
alanine-substituted GPR peptides (Fig. 3). These data confirm the
importance of the spatial relationship within the core GPR motif. These
data also indicate that the GPR domain must function as an intact unit
and that there are multiple points of contact between the GPR domain and G
.
|
Although the GPR peptide clearly prefers G
i over
G
o, subtle mutations within the core motif
differentially effect peptide interaction with the two G-proteins (Fig.
4A). A screen of the mutant
GPR peptides for selectivity indicated that inhibition of GTP
S
binding to G
o is completely eliminated by alanine
substitutions within the core GPR motif that only minimally altered
GTP
S binding to G
i (Fig. 4A). The
difference in the interaction of the GPR peptide with G
i
versus G
o is also observed by comparing the relative inhibition of GTP
S binding in the presence and absence of
magnesium. The inhibition of GTP
S binding to G
o is
much more sensitive to magnesium as compared with the effects of the
peptide on G
i (Fig. 4B). These data indicate
that the GPR peptides can differentially target G-protein
subunits.
Amino acids outside the GPR motif may also influence G-protein
selectivity or bioactivity (see Discussion in Ref.
4).3
|
The core GPR motif identified in the present study is indicated in
Sequence 1.
|
|
|
|
| |
ACKNOWLEDGEMENTS |
|---|
We thank Joe Blumer (Louisiana State University Health Sciences Center) for suggestions and review of this work. We also appreciate discussions with Michael Bernard (Medical University of South Carolina) and Stephen Sprang (University of Texas Southwestern); the footnoted communication from Randall Kimple, David Siderovski, and John Sondek (University of North Carolina School of Medicine); and the technical assistance of Jane Jourdan and Maureen Fallon.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants NS24821 and MH5993 (to S. M. L.) and National Science Foundation Grant MCB9870839 (to S. G. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Dept. of Pharmacology, MEB Suite 7103, LSUHSC, 1901 Perdido St., New Orleans, LA 70112. Tel.: 504-568-4744; Fax: 504-568-2361; E-mail: slanie@lsuhsc.edu.
Published, JBC Papers in Press, December 27, 2001, DOI 10.1074/jbc.C100699200
2 Y. K. Peterson and S. M. Lanier, unpublished observations.
3 R. Kimple, J. Sondek, and D. P. Siderovski, personal communication.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
RGS, regulator of G-protein signaling;
GPR, G-protein regulatory;
AGS, activator of G-protein signaling;
GTP
S, guanosine
5'-O-(3-thiotriphosphate);
GST, glutathione
S-transferase.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Ross, E. M., and Wilkie, T. M. (2000) Annu. Rev. Biochem. 69, 795-827[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Cismowski, M., Takesono, A., Ma, C., Lizano, J. S., Xie, S., Fuernkranz, H., Lanier, S. M., and Duzic, E. (1999) Nat. Biotechnol. 17, 878-883[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Takesono, A.,
Cismowski, M. J.,
Ribas, C.,
Bernard, M.,
Chung, P.,
Hazard, S., III,
Duzic, E.,
and Lanier, S. M.
(1999)
J. Biol. Chem.
274,
33202-33205 |
| 4. |
Peterson, Y. K.,
Bernard, M. L., Ma, H.,
Hazard, S., III,
Graber, S. G.,
and Lanier, S. M.
(2000)
J. Biol. Chem.
275,
33193-33196 |
| 5. |
Bernard, M. L.,
Peterson, Y. K.,
Chung, P.,
Jordan, J.,
and Lanier, S. M.
(2001)
J. Biol. Chem.
276,
1585-1593 |
| 6. |
Natochin, M.,
Lester, B.,
Peterson, Y. K.,
Bernard, M. L.,
Lanier, S. M.,
and Artemyev, N. O.
(2000)
J. Biol. Chem.
275,
40981-40985 |
| 7. | Ponting, C. P. (1999) J. Mol. Med. 77, 695-698[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Siderovski, D. P., Diverse-Pierlussi, M. A., and De Vries, L. (1999) Trends Biochem. Sci. 24, 340-341[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Pizzinat, N.,
Takesono, A.,
and Lanier, S. M.
(2001)
J. Biol. Chem.
276,
16601-16610 |
| 10. | Natochin, M., Gasimov, K. G., and Artemyev, N. O. (2001) Biochemistry 40, 5322-5328[Medline] [Order article via Infotrieve] |
| 11. |
De Vries, L.,
Fischer, T.,
Tronchere, H.,
Brothers, G. M.,
Strockbine, B.,
Siderovski, D. P.,
and Farquhar, M. G.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
14364-14369 |
| 12. |
Kimple, R. J., De,
Vries, L.,
Tronche`re, H.,
Behe, C. I.,
Morris, R. A.,
Farquhar, M. G.,
and Siderovski, D. P.
(2001)
J. Biol. Chem.
276,
29275-29281 |
| 13. | Mochizuki, N., Cho, G., Wen, B., and Insel, P. A. (1996) Gene (Amst.) 181, 39-43[CrossRef][Medline] [Order article via Infotrieve] |
| 14. | Yu, F. W., Morin, X., Cai, Y., Yang, X. H., and Chia, W. (2000) Cell 100, 399-409[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Schaefer, M., Schevchenko, A., Schevchenko, A., and Knoblich, J. A. (2000) Curr. Biol. 10, 353-362[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Bellaïche, Y., Radovic, A., Woods, D. F., Hough, C. D., Parmentier, M.-L., O'Kane, C. J., Bryant, P. J., and Schweisguth, F. (2001) Cell 106, 355-366[CrossRef][Medline] [Order article via Infotrieve] |
| 17. | Schaefer, M., Petronczki, M., Dorner, D., Forte, M., and Knoblich, J. A. (2001) Cell 107, 183-194[CrossRef][Medline] [Order article via Infotrieve] |
| 18. |
Jordan, J. D.,
Carey, K. D.,
Stork, P. J. S.,
and Iyengar, R.
(1999)
J. Biol. Chem.
274,
21507-21510 |
| 19. |
Meng, J.,
Glick, J. L.,
Polakis, P.,
and Casey, P. J.
(1999)
J. Biol. Chem.
274,
36663-36669 |
| 20. |
Luo, Y.,
and Denker, B. M.
(1999)
J. Biol. Chem.
274,
10685-10688 |
| 21. | Clawges, H. M., Depree, K. M., Parker, E. M., and Graber, S. G. (1997) Biochemistry 36, 12930-12938[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Bowers, S., Lanier, S. M., and Kalivas, P. (2001) Annual Meeting of the Society of Neuroscience, November 11-15, San Diego, CA, Abstract Program 977.6 |
This article has been cited by other articles:
![]() |
M. Sato, M. J. Cismowski, E. Toyota, A. V. Smrcka, P. A. Lucchesi, W. M. Chilian, and S. M. Lanier Identification of a receptor-independent activator of G protein signaling (AGS8) in ischemic heart and its interaction with Gbeta{gamma} PNAS, January 17, 2006; 103(3): 797 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Ja, A. Adhikari, R. J. Austin, S. R. Sprang, and R. W. Roberts A Peptide Core Motif for Binding to Heterotrimeric G Protein {alpha} Subunits J. Biol. Chem., September 16, 2005; 280(37): 32057 - 32060. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Cho, D.-U. Kim, and J. H. Kehrl RGS14 Is a Centrosomal and Nuclear Cytoplasmic Shuttling Protein That Traffics to Promyelocytic Leukemia Nuclear Bodies Following Heat Shock J. Biol. Chem., January 7, 2005; 280(1): 805 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Cao, M. J. Cismowski, M. Sato, J. B. Blumer, and S. M. Lanier Identification and Characterization of AGS4: A PROTEIN CONTAINING THREE G-PROTEIN REGULATORY MOTIFS THAT REGULATE THE ACTIVATION STATE OF Gi{alpha} J. Biol. Chem., June 25, 2004; 279(26): 27567 - 27574. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Sato, T. W. Gettys, and S. M. Lanier AGS3 and Signal Integration by G{alpha}s- and G{alpha}i-coupled Receptors: AGS3 BLOCKS THE SENSITIZATION OF ADENYLYL CYCLASE FOLLOWING PROLONGED STIMULATION OF A G{alpha}i-COUPLED RECEPTOR BY INFLUENCING PROCESSING OF G{alpha}i J. Biol. Chem., April 2, 2004; 279(14): 13375 - 13382. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Adhikari and S. R. Sprang Thermodynamic Characterization of the Binding of Activator of G Protein Signaling 3 (AGS3) and Peptides Derived from AGS3 with G{alpha}i1 J. Biol. Chem., December 19, 2003; 278(51): 51825 - 51832. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ghosh, Y. K. Peterson, S. M. Lanier, and A. V. Smrcka Receptor- and Nucleotide Exchange-independent Mechanisms for Promoting G Protein Subunit Dissociation J. Biol. Chem., September 12, 2003; 278(37): 34747 - 34750. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Blumer, M. L. Bernard, Y. K. Peterson, J.-i. Nezu, P. Chung, D. J. Dunican, J. A. Knoblich, and S. M. Lanier Interaction of Activator of G-protein Signaling 3 (AGS3) with LKB1, a Serine/Threonine Kinase Involved in Cell Polarity and Cell Cycle Progression: PHOSPHORYLATION OF THE G-PROTEIN REGULATORY (GPR) MOTIF AS A REGULATORY MECHANISM FOR THE INTERACTION OF GPR MOTIFS WITH Gi{alpha} J. Biol. Chem., June 20, 2003; 278(26): 23217 - 23220. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Kimple, F. S. Willard, and D. P. Siderovski The GoLoco Motif: Heralding a New Tango Between G Protein Signaling and Cell Division Mol. Interv., April 1, 2002; 2(2): 88 - 100. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |